Clinical Trials
26 trialsNCT02600949 2026-04-24
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT01795313 2026-02-05
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
University of Pittsburgh
Phase 1 Terminated
NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT04808245 2025-09-22
INTERCEPT-H3
German Cancer Research Center
Phase 1 Active not recruiting
NCT01803152 2024-07-03
Dendritic Cell Vaccine for Children and Adults With Sarcoma
University of Miami
Phase 1 Completed
NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting
NCT00788164 2023-08-31
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00142454 2022-10-10
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01808820 2022-07-20
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
University of Miami
Phase 1 Completed
NCT03982004 2021-06-21
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Washington University School of Medicine
Phase 1 Terminated
NCT04072900 2020-04-28
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Phase 1 Unknown
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT01400672 2020-03-18
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT02276300 2019-11-20
HER2
Technical University of Munich
Phase 1 Completed
NCT02234921 2018-10-11
DRibble
UbiVac
Phase 1 Completed
NCT00988559 2018-07-09
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01171469 2017-12-02
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01902771 2017-03-10
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
University of Miami
Phase 1 Terminated
NCT00865644 2017-01-10
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Massachusetts General Hospital
Phase 1 Completed
NCT01264731 2016-12-16
MEL53
University of Virginia
Phase 1 Completed
NCT02689726 2016-12-02
Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
Genticel
Phase 1 Terminated
NCT00453050 2015-05-06
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
National Cancer Institute (NCI)
Phase 1 Completed
NCT01403285 2014-05-19
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Immatics Biotechnologies GmbH
Phase 1 Terminated
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01788007 2014-01-22
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT00079300 2013-04-26
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed